Bristol Myers Squibb Announces Positive Topline Results from the Interim Analysis of Phase 3 ACTION-1 for RYZ101, RayzeBio’s Radiopharmaceutical Therapy, in Patients with GEP-NETs
Phase 3positiveRYZ101Positive
AI Analysis
Summary
Bristol Myers Squibb announced positive topline results from the planned interim analysis of the Phase 3 ACTION-1 trial of RYZ101, a radiopharmaceutical therapy developed by its subsidiary RayzeBio, in patients with GEP-NETs. Specific efficacy data were not included in the provided excerpt.
Clinical Trial Data
Phase
Phase 3
NCT ID
Outcome Details
Positive topline results from the planned interim analysis of the Phase 3 ACTION-1 trial of RYZ101, a radiopharmaceutical therapy, in patients with GEP-NETs. Detailed efficacy data not provided in the available text.
Importance:8/10
Sentiment:
0.70
Phase 3topline resultsinterim analysisradiopharmaceuticalGEP-NETsoncologyRayzeBioACTION-1
Related Companies
Read the original article
Published by Drugs.com Clinical Trial Results on October 12, 2026 7:10 PM